Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant HPV 9-Valent Vaccine in Chinese Males
NCT06866574Phase 3Active, not recruiting
- Sponsor
- Xiamen University
- Start
- Apr 2025
- Primary completion
- Sep 2031
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, genital warts, anal cancer, penile cancer, anal intraepithelial neoplasia (AIN), sponsored by Xiamen University. Started Apr 2025; status: active, not recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectiongenital wartsanal cancerpenile canceranal intraepithelial neoplasia (AIN)
Beyond the preview
Go deeper on NCT06866574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06866574.